Zai Lab's Zoci Shows Strong Intracranial Responses in SCLC Brain Metastases
Event summary
- Zai Lab's zocilurtatug pelitecan (zoci) demonstrated rapid and robust intracranial responses in patients with extensive stage small cell lung cancer (ES-SCLC) and brain metastases, with a 53.7% intracranial objective response rate (iORR).
- Preliminary data from a Phase 1b/2 trial showed zoci achieved a 38.2% overall response rate in patients with extrapulmonary neuroendocrine carcinomas (epNECs).
- Zai Lab plans to initiate three registration-enabling studies for zoci by the end of 2026, targeting SCLC and epNEC indications.
- The company will also present preclinical data on ZL-6201 (LRRC15 ADC) and ZL-1222 (PD-1/IL-12 immunocytokine) at the AACR Annual Meeting 2026.
The big picture
Zai Lab's positive clinical data for zoci underscores the growing importance of targeted therapies in oncology, particularly for aggressive cancers with limited treatment options. The company's ability to leverage its U.S.-China infrastructure could accelerate its goal of delivering a global oncology launch, potentially reshaping the competitive landscape for SCLC and neuroendocrine carcinoma treatments.
What we're watching
- Regulatory Pathway
- Whether Zai Lab can successfully navigate the regulatory process for zoci's registration-enabling studies and secure approvals by the end of 2026.
- Pipeline Diversification
- The pace at which Zai Lab advances its other pipeline candidates, particularly ZL-6201 and ZL-1222, following promising preclinical data.
- Market Differentiation
- How zoci's best-in-class safety profile and intracranial efficacy will position it against existing therapies for SCLC and epNEC.
Our editorial coverage:
Related topics